title: Nivolumab + ipilimumab ups melanoma response.
abstract: For patients with advanced melanoma, the combination of ipilimumab and nivolumab yields better responses than ipilimumab alone. However, the two-drug combination is much more likely to cause side effects than the monotherapy.
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal